Clinical Trials Logo
  1. Home
  2. Adult Acute Myeloid Leukemia
  3. NCT06045819

Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)

Adult Acute Myeloid Leukemia Clinical Trial

Official title:
Study of the Association Between Residual Venetoclax Plasma Concentration and Composite Complete Remission in Adults With Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (PREDICLAX)

Clinical Trial Summary

Background: In combination with hypomethylating drugs, venetoclax has recently changed the therapeutic management of patients with newly diagnosed acute myeloid leukemia (AML) for whom standard induction chemotherapy was not an option. Over and above the clinical benefits of this combination, the data show that more than half the patients did not show remission criteria, even after the first month's exposure to venetoclax. Hypothesis: To compare the mean residual venetoclax plasma concentrations obtained in patients who went into complete composite remission versus those who did not go into remission at the end of the first cycle of venetoclax + azacitidine treatment. Method: According to the French law, this is a multicenter, non-comparative, open-label, single-arm, interventional study with minimal risks and constraints. Selection, information and inclusion will concern adult patients (≥60 years) with a confirmed diagnosis of AML according to ELN 2022 guidelines. Included patients will be treated as standard care with a combination of venetoclax+azacitidine. This research protocol will not modify their usual care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06045819
Study type Observational
Source University Hospital, Caen
Contact Sylvain Chantepie, MD
Phone +33231272107
Email chantepie-s@chu-caen.fr
Status Recruiting
Phase
Start date April 8, 2024
Completion date January 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT01146223 - Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia N/A
Completed NCT01295710 - Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) Phase 3
Completed NCT01807091 - Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome N/A
Recruiting NCT03114670 - Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT Phase 1
Recruiting NCT05429632 - Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Phase 3
Active, not recruiting NCT03226418 - Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Phase 2
Recruiting NCT05262465 - Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML N/A
Recruiting NCT06329999 - A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML N/A
Completed NCT01484015 - Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Phase 1
Completed NCT01041443 - 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Phase 1
Not yet recruiting NCT03283228 - Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia N/A
Completed NCT01251575 - Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Phase 2
Withdrawn NCT00101140 - Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Phase 2